

Ilaria Cavallari, MD, PhD

PRESENT POSITION

Since August 2017 Cardiologist, 'Campus Bio-Medico di Roma' Hospital, Rome, Italy
 Since September 2019 Coordinator of the Mentoring Programme, Master Degree Program in Medicine and Surgery (international english course), at 'Università Campus Bio-Medico di Roma', Rome, Italy

EDUCATION

July 9th 2020 PhD in Integrated Biomedical Sciences and Bioethics, Curriculum Endocrinology, at 'Università Campus Bio-Medico di Roma', Rome, Italy, under the supervision of Professors Germano Di Sciascio, Francesco Grigioni and Paolo Pozzilli
Final Thesis (experimental): “Prevention and Management of Cardiovascular Disease in Metabolic Disorders”.

July 12th 2017 Board Certified in Cardiology, 'Università Campus Bio-Medico di Roma', Rome, Italy
Final grade: 50/50 cum laude
Final Thesis (experimental): “Clinical Events after Interruption of Anticoagulation in Patients with Atrial Fibrillation: a Subgroup Analysis From ENGAGE AF-TIMI 48 Trial”. Supervisor: Professor Germano Di Sciascio; co-supervisor: Professor Robert Giugliano, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

July 2012-July 2017 Clinical Fellowship in Cardiology at 'Università Campus Bio-Medico di Roma', Rome, Italy, under the supervision of Professor Germano Di Sciascio

May 2015-May 2016 Post-Doctoral Research Fellow at TIMI Study Group, Department of Medicine, Division of Cardiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, US, under the supervision of Professor Marc Steven Sabatine and Professor Eugene Braunwald
 Training on clinical trial design and execution, hypothesis framing, statistical analyses planning and data interpretation. Working in the TIMI Medical Hotline consulting investigators from all over the world about ongoing trials. Person in charge of FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) Hotline. ClinicalTrials.gov Identifier: NCT01764633
Major project: co-investigator in LOFT (Long-Term Odanacatib Fracture Trial) ClinicalTrials.gov Identifier: NCT00529373. Draft clinical events committee adjudication charter and forms and the statistical analysis plan, coordinate and track collection and transfer of clinical dossiers to TIMI safety desk

March-April 2016 Intermediate Biostatistics Course for Medical Researchers, Brigham and Women’s Hospital, Boston, US, Professor Robert Goldman

December 2015 'Advanced Cardiovascular Life Support' Certification for Healthcare Providers of the American Heart Association

October 2015	Introduction to Meta-Analysis and Systematic Review Methods, Harvard Catalyst's Biostatistics Program, Boston, US
Sept-October 2015	Introductory Biostatistics for Medical Researchers Course, Brigham and Women's Hospital, Boston, US, Professor Robert Goldman
February 2012	Italian license to practice Medicine (final grade 270/270)
July 18 th , 2011	Degree in Medicine and Surgery at 'Università Campus Bio-Medico di Roma', Rome, Italy <u>Degree final grade</u> : 110/110 cum laude <u>Degree Thesis</u> (experimental): "Percutaneous closure of patent foramen ovale: results from a longitudinal prospective study". Supervisor: Professor Germano Di Sciascio; co-supervisor: Doctor Giuseppe Patti
March 2009-July 2011	Internship at the Department of Cardiovascular Sciences, 'Università Campus Bio-Medico di Roma', Rome, Italy. Supervisor: Professor Germano Di Sciascio
May 2011	Successfully passed the 'Italian Resuscitation Council Certificate Basic Life Support-Defibrillation (BLS-D) for Healthcare Providers'
August-Nov 2010	Erasmus student at the Department of Cardiovascular Medicine, 'University Hospitals Leuven' (Belgium), under the supervision of Professor Frans Van De Werf, attending cardiac catheterization laboratories, intensive coronary care unit and echocardiography laboratories
July 2008	Visiting student at the Department of Cardiology, 'Clinica Universitaria de Navarra', Pamplona (Spain), under the supervision of Professor José Maria Araquistain Echabe
Sept 2006-June 2007	Internship in the Department of Human Anatomy attending the Microscopic Anatomy laboratory
September 2005	Winner of the competition for the admission to the Faculty of Medicine at 'Università Campus Bio-Medico di Roma', Rome, Italy Winner of the competition for the admission to the Faculty of Medicine at 'Università degli Studi di Tor Vergata', Rome, Italy
February-March 2005	Attended the European Course of First Aid, organized by the Italian Red Cross
July 2005	Scientific High School Diploma - final grade: 100/100

RESEARCH METRICS (Scopus)

h-index 14

documents 62
 citations 716

PEER-REVIEWED PUBLICATIONS

1. Patti G, Mangiacapra F, Ricottini E, Cannatà A, Cavallari I, Vizzi V, D'Ambrosio A, Dicuonzo G, Di Sciascio G. Correlation of Platelet Reactivity and C-Reactive Protein Levels to Occurrence of Peri-Procedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the ARMYDA-CRP Study). *Am J Cardiol*. 2013;111(12):1739-44.
2. Mangiacapra F, Cavallari I, Barbato E, Ricottini E, Patti G, Vizzi V, D'Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G. Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention. *Am J Cardiol*. 2014 Apr 1;113(7):1124-9.
3. Cavallari I, Nusca A, Ricottini E, Di Sciascio G. Prognostic role of platelet reactivity in patients with acute coronary syndromes. *Cardiol Rev*. 2014 Nov-Dec;22(6):313-8.
4. Patti G, Cavallari I. Variability in the benefit of the novel oral anticoagulant agents in patients with non-valvular atrial fibrillation. *Intern Emerg Med* 2015;10(3):395-6.
5. Patti G, Bennett R, Seshasai SR, Cannon CP, Cavallari I, Chello M, Nusca A, Mega S, Caorsi C, Spadaccio C, On YK, Mannacio V, Berkan O, Yilmaz MB, Katrancioglu N, Ji Q, Kourliouros A, Baran C, Pasceri V, Akar AR, Kaski JC, Di Sciascio G, Ray KK. Statin pre-treatment and risk of in-hospital atrial fibrillation among patients undergoing cardiac surgery: a collaborative meta-analysis of 11 randomized controlled trials. *Europace* 2015;17(6):855-63.
6. Mangiacapra F, Cavallari I, Ricottini E, Pellicano M, Barbato E, Di Sciascio G. High platelet reactivity and periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: A significant association beyond definitions. *Int J Cardiol* 2015;190:124-125.
7. Cavallari I*, Mega S*, Goffredo C, Patti G, Chello M, Di Sciascio G. Hand-held Echocardiography in the setting of pre-operative cardiac evaluation of patients undergoing non-cardiac surgery: results from a randomized pilot study. *Int J Cardiovasc Imaging* 2015;31(5):995-1000. *Equal contribution.
8. Patti G, Cavallari I. Patients with atrial fibrillation and CHA₂DS₂-VASc score 1: "To anticoagulate or not to anticoagulate? That is the question!". *Heart Rhythm* 2015;12:2515-20.
9. Patti G, Cavallari I. Comment on "Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes". *N Engl J Med* 2015;373:1474-5.
10. Patti G, Ricottini E, De Luca L, Cavallari I. Safety and Efficacy of Switching From Clopidogrel to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: A Study-level Meta-analysis From 15 Studies. *J Cardiovasc Pharmacol* 2016;67(4):336-43.
11. Annibali O, Chiodi F, Cenfra N, Sarlo C, Mega S, Cavallari I, Rago A, Tomassini S, Mecarocci S, Cimino G, Avvisati G. 'Real Life' experience in a 'difficult to treat' patient population of non-Hodgkin lymphomas using the R-COMP regimen. *Leuk Lymphoma* 2016 Apr 11:1-4.
12. Patti G, Cavallari I. Extended duration dual antiplatelet therapy in patients with myocardial infarction: a study-level meta-analysis of controlled randomized trials. *Am Heart J*. 2016;176:36-43.
13. Maddaloni E*, Cavallari I*, De Pascalis M, Keenan H, Park K, Manfrini S, Buzzetti R, Patti G, Di Sciascio G, Pozzilli P. Relation of Body Circumferences to Cardiometabolic Disease in Overweight-Obese Subjects. *Am J Cardiol*. 2016;118(6):822-27. *Equal contribution.
14. Ricciardi D, Cavallari I, Creta A, Di Giovanni G, Calabrese V, Di Belardino N, Mega S, Colaioni I, Ragni L, Proscia C, Nenna A, Di Sciascio G. Impact of the high-frequency cutoff of bandpass filtering on ECG quality and clinical interpretation: A comparison between 40Hz and 150Hz cutoff in a surgical preoperative adult outpatient population. *J Electrocardiol*. 2016;49:691-695.
15. Bressi E, Mangiacapra F, Ricottini E, Cavallari I, Colaioni I, Di Gioia G, Creta A, Di Sciascio G. Relation of Neutrophil to Lymphocyte Ratio With Periprocedural Myocardial Damage in Patients Undergoing Elective Percutaneous Coronary Intervention. *Am J Cardiol*. 2016;118(7):980-4.

16. Patti G, Pengo V, Marcucci R, Cirillo P, Renda G, Santilli F, Calabrò P, De Caterina AR, Cavallari I, Ricottini E, Parato VM, Zoppellaro G, Di Gioia G, Sedati P, Cicchitti V, Davì G, Golia E, Pariggiano I, Simeone P, Abbate R, Prisco D, Zimarino M, Sofi F, Andreotti F, De Caterina R; Working Group of Thrombosis of the Italian Society of Cardiology. The left atrial appendage: from embryology to prevention of thromboembolism. *Eur Heart J*. 2017;38(12):877-87.
17. Cavallari I, Bonaca MP. Antiplatelet Therapy for Secondary Prevention After Acute Myocardial Infarction. *Interv Cardiol Clin*. 2017;6:119-129.
18. Patti G, Di Gioia G, Cavallari I, Nenna A. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study-level meta-analysis of phase III randomized trials. *Diabetes Metab Res Rev*. 2017; 33 (3).
19. Patti G, Lucerna M, Cavallari I, Ricottini E, Renda G, Pecan L, Romeo F, Le Heuzey JY, Zamorano JL, Kirchhof P, De Caterina R. Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF. *J Am Coll Cardiol*. 2017;69(4):409-419.
20. Patti G, Lucerna M, Pecan L, Siller-Matula JM, Cavallari I, Kirchhof P, De Caterina R. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (PREvention of Thromboembolic Events-European Registry in Atrial Fibrillation). *J Am Heart Assoc*. 2017;6(7).
21. Patti G, Cavallari I, Antonucci E, Calabrò P, Cirillo P, Gresele P, Palareti G, Pengo V, Pignatelli P, Ricottini E, Marcucci R. Prevalence and Predictors of Dual Antiplatelet Therapy Prolongation Beyond One Year in Patients with Acute Coronary Syndrome. *Plos One* 2017. In press.
22. Cavallari I, Morrow DA, Creager MA, Olin J, Bhatt DL, Steg PG, Storey RF, Cohen M, Scirica BS, Piazza G, Goodrich EL, Braunwald E, Sabatine MS, Bonaca MP. Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. *Circulation*. 2018 Feb 13;137(7):684-692.
23. Cavallari I, Patti G. Meta-Analysis Comparing the Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. *Am J Cardiol*. 2018 Mar 15;121(6):718-724.
24. Cavallari I, Ruff CT, Nordio F, Deenadayalu N, Shi M, Lanz H, Rutman H, Mercuri MF, Antman EM, Braunwald E, Giugliano RP. Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. *Int J Cardiol*. 2018 Apr 15;257:102-107.
25. Mangiacapra F, Colaïori I, Ricottini E, Creta A, Di Gioia G, Cavallari I, Bressi E, Capuano M, Barbato E, Di Sciascio G. Impact of platelet reactivity on 5-year clinical outcomes following percutaneous coronary intervention: a Landmark analysis. *J Thromb Thrombolysis*. 2018 May;45(4):496-503.
26. Cavallari I, Cannon CP, Braunwald E, Goodrich EL, Im K, Lukas MA, O'Donoghue ML. Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome. *Eur J Prev Cardiol*. 2018 May;25(8):830-838.
27. Cavallari I, Patti G. Clinical effects with inhibition of multiple coagulative pathways in patients admitted for acute coronary syndrome. *Intern Emerg Med*. 2018 Mar 21. doi: 10.1007/s11739-018-1834-x. [Epub ahead of print]
28. Ricottini E, Mangiacapra F, Nusca A, Melfi R, Cavallari I, Miglionico M, Gallo P, Pozzilli P, Di Sciascio G. Relation of Platelet Indexes to Platelet Reactivity and Periprocedural Myocardial Infarction in Patients Who Underwent Percutaneous Coronary Angioplasty. *Am J Cardiol*. 2018 May 1;121(9):1027-1031.
29. Maddaloni E, Cavallari I, Napoli N, Conte C. Vitamin D and Diabetes Mellitus. *Front Horm Res*. 2018;50:161-176.
30. Patti G, Cavallari I, Hanon O, De Caterina R. The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly. *Int J Cardiol*. 2018 Aug 15;265:118-124.
31. Patti G, Ricottini E, Nenna A, Cavallari I, Antonucci E, Calabrò P, Cirillo P, Gresele P, Palareti G, Pengo V, Pignatelli P, Bisignani A, Marcucci R. Impact of Chronic Renal Failure on Ischemic and Bleeding

- Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). *Am J Cardiol.* 2018 Sep 15;122(6):936-943.
32. Patti G, Cavallari I, Andreotti F, Calabrò P, Cirillo P, Denas G, Galli M, Golia E, Maddaloni E, Marcucci R, Parato VM, Pengo V, Prisco D, Ricottini E, Renda G, Santilli F, Simeone P, De Caterina R; Working Group on Thrombosis of the Italian Society of Cardiology. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. *Nat Rev Cardiol.* 2019 Feb;16(2):113-130.
 33. Bressi E, Mangiacapra F, Ricottini E, Cavallari I, Colaïori I, Di Gioia G, Creta A, Capuano M, Viscusi MM, Di Sciascio G. Impact of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio on 5-Year Clinical Outcomes of Patients with Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention. *J Cardiovasc Transl Res.* 2018 Dec;11(6):517-523.
 34. Cavallari I, Delli Veneri A, Maddaloni E, Melfi R, Patti G, Napoli N, Pozzilli P, Di Sciascio G. Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes. *Curr Diab Rep.* 2018 Oct 29;18(12):138.
 35. Cavallari I, Maddaloni E. Cardiovascular effects of SGLT-2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand. *Diabetes Metab Res Rev.* 2019 May;35(4):e3124.
 36. Calabrò P, Moscarella E, Gragnano F, Cesaro A, Pafundi PC, Patti G, Cavallari I, Antonucci E, Cirillo P, Pignatelli P, Palareti G, Sasso FC, Pengo V, Gresele P, Marcucci R; START-ANTIPLATELET collaborators, Conte M, Fimiani F, Di Serafino L, Del Pinto M, Denas G, Pastori D, Eleonora C, Fierro T. Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). *Am J Cardiol.* 2019;124(11):1662-1668.
 37. McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS; LOFT Investigators. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. *Lancet Diabetes Endocrinol.* 2019 Dec;7(12):899-911.
 38. Mangiacapra F, Bressi E, Colaïori I, Ricottini E, Cavallari I, Capuano M, Viscusi MM, Spoto S, Barbato E, Di Sciascio G. Interaction Between Diabetes Mellitus and Platelet Reactivity in Determining Long-Term Outcomes Following Percutaneous Coronary Intervention. *J Cardiovasc Transl Res.* 2020 Aug;13(4):668-675
 39. Cavallari I, Verolino G, Romano S, Patti G. Efficacy and Safety of Non-Vitamin K Oral Anticoagulants in Patients With Atrial Fibrillation and Cancer: a Study-Level Meta-Analysis. *Thromb Haemost.* 2020 Feb;120(2):314-321
 40. Cavallari I, Patti G. Primum non nocere does not justify clinical inertia for stroke prevention in elderly patients with atrial fibrillation in the era of direct oral anticoagulants. *Eur J Intern Med.* 2020 Jan;71:11-12.
 41. Patti G, Lio V, Cavallari I, Gragnano F, Riva L, Calabrò P, Di Pasquale G, Pengo V, Rubboli A. Terapie antitrombotiche in pazienti con infezione da SARS-CoV-2: dalle attuali evidenze alle ragionevoli raccomandazioni – Position paper del Gruppo di Studio Aterosclerosi, Trombosi e Biologia Vascolare [Antithrombotic treatments in patients with SARS-CoV-2 infection: from current evidence to reasonable recommendations - A position paper from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology]. *G Ital Cardiol (Rome).* 2020 Jul;21(7):489-501.
 42. Gragnano F, Moscarella E, Calabrò P, Cesaro A, Pafundi PC, Ielasi A, Patti G, Cavallari I, Antonucci E, Cirillo P, Pignatelli P, Palareti G, Pelliccia F, Gaudio C, Sasso FC, Pengo V, Gresele P, Marcucci R; START-ANTIPLATELET Collaborators. Clopidogrel versus ticagrelor in high-bleeding risk patients

- presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. *Intern Emerg Med*. 2021 Mar;16(2):379-387.
43. Cavallari I, Maddaloni E, Peralice S, Mulè MT, Buzzetti R, Ussia GP, Pozzilli P, Grigioni F. The Vicious Circle of Left Ventricular Dysfunction and Diabetes: From Pathophysiology to Emerging Treatments. *J Clin Endocrinol Metab*. 2020 Sep 1;105(9):dgaa427. doi: 10.1210/clinem/dgaa427.
 44. Calabrò P, Gragnano F, Cesaro A, Marsico F, Pariggiano I, Patti G, Moscarella E, Cavallari I, Sardu C, Parato VM, Renda G, Niccoli G, Marcucci R, De Caterina R; Working Group of Thrombosis and; Working Group of Interventional Cardiology of the Italian Society of Cardiology. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence. *Arch Cardiovasc Dis*. 2020 Oct;113(10):642-651.
 45. Patti G, Lio V, Cavallari I, Gragnano F, Riva L, Calabrò P, Di Pasquale G, Pengo V, Rubboli A; Italian Study Group on Atherosclerosis, Thrombosis, Vascular Biology. Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology. *Am J Cardiovasc Drugs*. 2020 Dec;20(6):559-570.
 46. Cavallari I, Patti G. Early risk of mortality, cardiovascular events, and bleeding in patients with newly diagnosed atrial fibrillation. *Eur Heart J Suppl*. 2020 Nov 18;22(Suppl L):L110-L113.
 47. Marston NA, Melloni GEM, Gurmu Y, Bonaca MP, Kamanu FK, Roselli C, Lee C, Cavallari I, Giugliano RP, Scirica BM, Bhatt DL, Steg PG, Cohen M, Storey RF, Keech AC, Raz I, Mosenzon O, Braunwald E, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT. Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. *Circ Genom Precis Med*. 2021 Feb;14(1):e003006.
 48. Cavallari I, Maddaloni E, Gragnano F, Patti G, Antonucci E, Calabrò P, Cirillo P, Gresele P, Palareti G, Pengo V, Pignatelli P, Marcucci R; START-ANTIPLATELET collaborators. Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. *Intern Emerg Med*. 2021 Sep;16(6):1583-1591.
 49. Cavallari I, Maddaloni E, Grigioni F. Implementing the treatment of heart failure with SGLT-2 inhibitors and sacubitril-valsartan: does money matter? *Eur J Prev Cardiol*. 2020 Dec 24;zwaa153. doi: 10.1093/eurjpc/zwaa153.
 50. Paolucci L, Mangiacapra F, Viscusi MM, Bressi E, Colaïori I, Ricottini E, Cavallari I, Nusca A, Melfi R, Ussia GP, Grigioni F. Prediction of 5-Year Mortality in Patients with Chronic Coronary Syndrome Treated with Elective Percutaneous Coronary Intervention: Role of the ACEF Score. *J Cardiovasc Transl Res*. 2021 Dec;14(6):1125-1130.
 51. Cavallari I, Bhatt DL, Steg PG, Leiter LA, McGuire DK, Mosenzon O, Im K, Raz I, Braunwald E, Scirica BM. Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial. *J Am Coll Cardiol*. 2021 Apr 13;77(14):1837-1840.
 52. Mangiacapra F, Sticchi A, Bressi E, Mangiacapra R, Viscusi MM, Colaïori I, Ricottini E, Cavallari I, Spoto S, Ussia GP, Ferraro PM, Grigioni F. Impact of Chronic Kidney Disease and Platelet Reactivity on Clinical Outcomes Following Percutaneous Coronary Intervention. *J Cardiovasc Transl Res*. 2021 Apr 13. doi: 10.1007/s12265-021-10126-8. Epub ahead of print.
 53. Nusca A, Tuccinardi D, Peralice S, Giannone S, Carpenito M, Monte L, Watanabe M, Cavallari I, Maddaloni E, Ussia GP, Manfrini S, Grigioni F. Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease. *Front Pharmacol*. 2021 May 12;12:670155. doi: 10.3389/fphar.2021.670155.
 54. Del Toro R*, Cavallari I*, Tramontana F, Park K, Strollo R, Valente L, De Pascalis M, Grigioni F, Pozzilli P, Buzzetti R, Napoli N, Maddaloni E. Association of bone biomarkers with advanced atherosclerotic disease in people with overweight/obesity. *Endocrine*. 2021 Aug;73(2):339-346. *Equal contribution.
 55. Cavallari I, Maddaloni E, Gragnano F, Patti G, Antonucci E, Calabrò P, Cirillo P, Gresele P, Palareti G, Pengo V, Pignatelli P, Marcucci R; START-ANTIPLATELET collaborators. Ischemic and bleeding risk

- by type 2 diabetes clusters in patients with acute coronary syndrome. *Intern Emerg Med*. 2021 Sep;16(6):1583-1591.
56. Viscusi MM, Mangiacapra F, Bressi E, Sticchi A, Colaioni I, Capuano M, Ricottini E, Cavallari I, Spoto S, Di Sciascio G, Ussia GP, Grigioni F. Platelet reactivity and clinical outcomes following percutaneous coronary intervention in complex higher-risk patients. *J Cardiovasc Med (Hagerstown)*. 2021 Sep 20. doi: 10.2459/JCM.0000000000001248. Epub ahead of print.
 57. Maddaloni E, D'Onofrio L, Siena A, Luordi C, Mignogna C, Amendolara R, Cavallari I, Grigioni F, Buzzetti R. Impact of cardiovascular disease on clinical outcomes in hospitalized patients with Covid-19: a systematic review and meta-analysis. *Intern Emerg Med*. 2021 Oct;16(7):1975-1985.
 58. Cavallari I, Maddaloni E, Nusca A, Tuccinardi D, Buzzetti R, Pozzilli P, Grigioni F. SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness. *Am J Cardiovasc Drugs*. 2021 Nov 17. doi: 10.1007/s40256-021-00508-3. Epub ahead of print.
 59. Cesaro A, Gragnano F, Calabrò P, Moscarella E, Santelli F, Fimiani F, Patti G, Cavallari I, Antonucci E, Cirillo P, Pignatelli P, Palareti G, Pelliccia F, Bossone E, Pengo V, Gresele P, Marcucci R; START-ANTIPLATELET collaborators. Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. *Int J Cardiol*. 2021 Dec 15;345:7-13.
 60. Cavallari I, Patti G, Maddaloni E, Veneziano F, Mangiacapra F, Ricottini E, Buzzetti R, Ussia GP, Grigioni F. Association Between Platelet Reactivity and Long-Term Bleeding Complications After Percutaneous Coronary Intervention According to Diabetes Status. *Am J Cardiol* 2022, Epub Ahead of Print.

INVITED PUBLICATIONS

1. Mangiacapra F, Cavallari I, Patti G. Bisogna somministrare i farmaci antiaggreganti prima o dopo la visualizzazione dell'albero coronarico? *Giornale Italiano di Cardiologia Invasiva* 2012;4:3-7.
2. Mangiacapra F, Cavallari I, Proscia C, Ricottini E, Di Sciascio G. Ischemic and bleeding events after percutaneous coronary intervention: the role of platelet reactivity. *Treatment Strategies Cardiology*, Volume 4 Issue 2, 79-82.
3. Cavallari I. Perioperative management of Patients Receiving Novel Oral Anticoagulants. <http://www.acc.org>. September 3, 2015. Accessed <http://www.acc.org/education-and-meetings/patient-case-quizzes/perioperative-management-of-patients-receiving-novel-oral-anticoagulants>.
4. Patti G, Cavallari I. Controversia sulla chiusura percutanea dell'auricola. Con l'avvento dei NAO l'indicazione è più ristretta. *Giornale Italiano di Cardiologia Invasiva* 2015;4:36-39.
5. Cavallari I, Patti G. Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation. *Anatol J Cardiol*. 2018 Jan;19(1):67-71.
6. Patti G, Cavallari I. [Antithrombotic approaches in patients undergoing left atrial appendage occlusion: current evidence and future perspectives]. *G Ital Cardiol (Rome)*. 2019 Mar;20(3):23-27.
7. Calabrò P, Gragnano F, Cesaro A, Pariggiano I, Patti G, Cavallari I, Parato VM, Renda G, De Caterina R; a nome del Gruppo di Studio sulla Trombosi della Società Italiana di Cardiologia. [Atrial and left atrial appendage thrombosis in patients with atrial fibrillation: from pathophysiology to treatment]. *G Ital Cardiol (Rome)*. 2019 Jun;20(6):374-383.
8. Cavallari I, De Filippis A, Nobile E, Veneziano F, Melfi R, Nusca A, Ussia GP, Grigioni F. Aspirina in prevenzione primaria nel diabete mellito: rassegna delle evidenze e delle raccomandazioni. *L'Endocrinologo* 2021. Epub Ahead of Print.

MONOGRAPH

1. Patti G, Cavallari I. Monacolin Product Monograph. Therapy Perspectives for Rational Drug Use & Disease Management. Springer Healthcare. Year XIX, N.4, March 2016.

BOOK CHAPTERS

1. Patti G, Cavallari I, Kaski JC. Atrial Fibrillation and Percutaneous Coronary Intervention. Case-based Recommendations on Oral Anticoagulation, Antiplatelet Therapy and Stenting. Editors: Gregory YH Lip and Andrea Rubboli. Chapter 10. Urgent surgery early after coronary stenting in a patient with atrial fibrillation on triple therapy of NOAC (a factor Xa-inhibitor), aspirin and clopidogrel.
2. Cavallari I, Bonaca MP. Antiplatelet and Anticoagulation Therapy In PCI, An Issue of Interventional Cardiology Clinics, 1st Edition. Elsevier. Editor-in-Chief: Matthew J. Price, Editors: Matthew J. Price and Dominick J. Angiolillo. Chapter 10. Antiplatelet Therapy for Secondary Prevention After Acute Myocardial Infarction.

CLINICAL TRIALS AND MULTICENTER STUDIES

Principal Investigator 'Studio Pilota su Edoxaban per la Risoluzione della Trombosi Atriale Sinistra in Pazienti con Fibrillazione Atriale non Valvolare' (EDOXYBAN in AF (EDO-SP-01-2015)

Study Coordinator 'European Multinational Prolongation Registry on Prevention of Thromboembolic Events in Atrial Fibrillation' (PREFER in AF PROLONGATION).

Study Investigator of the following studies:

1. 'PREvention oF thromboembolic events - European Registry in Atrial Fibrillation' (PREFER in AF).
2. 'Antithrombotic treatment as Secondary (2) Prevention Among patients with a recent myoCardial infarction Event' (A2SPACE).
3. 'Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation' (AEGEAN). ClinicalTrials.gov Identifier: NCT01884350.
4. 'Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)' (EMANATE). ClinicalTrials.gov Identifier: NCT02100228.
5. 'The START-Antiplatelet Register: A Multicenter Observational Prospective Study to Assess the Risk-Benefits of Antithrombotic Therapy in ACS Patients'.
6. 'Studio italiano della fase post acuta delle Sindromi Coronariche (studio PACSI)'. MK-0653-834.
7. ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation)
8. ACTION 1 (cArdiopulmonary exerCise Test assessing multiple bIOmarkers iN type 1 diabetes)
9. VESALIUS-CV (A Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke)
10. SANTORINI (The Treatment of High and Very high risk dyslipidaemic pAtients for the PreveNTion of CardiOvasculaR Events in Europe – a MultInatioNal Observational Study)

COMPETITIVE GRANTS

Study investigator – University Grant: 'Oxidative post-translational modifications of Insulin as biomarkers of type 1 DIAbetes (OxIDIA)'.

HONORS AND AWARDS

Finalist, Young Investigators Award (≤ 35 yrs) Session Stroke at the European Society of Cardiology (ESC) Congress 2016, August 27th-31th, Rome, Italy.

'Clinical Events after Interruption of Anticoagulation in Patients with Atrial Fibrillation: a Subgroup Analysis From ENGAGE AF-TIMI 48 Trial'.

Winner of Clinical Cases Contest – Management of Antithrombotic Therapy in Atrial Fibrillation Patients with Acute Coronary Syndrome, Experience Meets Evidence: Eliquibrium 2017, March 10th-11th, Rome, Italy.

Best poster presentation for the topic “Atrial Fibrillation” at the European Congress of Cardiology (ESC) Congress 2017, August 26th-30th, Barcelona, Spain.

'Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF'.

Awarded as Rising Star During the 7th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), April 12th-13th 2019, Sorrento, Italy.

'Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome'.

SOCIETES

Italian Society of Cardiology (SIC) – Member

Italian Society of Cardiology (SIC) – Member of Nucleus SIC Thrombosis Group of Study since December 2016

Italian Society of Cardiovascular Research (SIRC) – Member

European Society of Cardiology (ESC) – Member

American College of Cardiology (ACC) – Member as Fellow in Training

Atherosclerosis, Thrombosis and Vascular Biology (ATBV) – Member of the Elected Board 2020-2024

LANGUAGES

English - Fluent

December 2004 – 'Certificate in Advanced English', University of Cambridge

June 2003 – 'First Certificate in English', University of Cambridge

April 2003 – Trinity College Examination, Grade 8 'Spoken English for Speakers of Other Languages'

French - Basic

Rome, 21th January 2022

